Protocol for the examination of specimens from patients with primary non-small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lung

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 10, 2009, Pages 1552-1559

  Butnor, Kelly J ^a   Beasley, Mary Beth ^b   Cagle, Philip T ^c   Grunberg, Steven M ^a   Kong, Feng Ming ^d   Marchevsky, Alberto ^e   Okby, Nader T ^f   Roggli, Victor L ^g   Suster, Saul ^h   Tazelaar, Henry D ⁱ   Travis, William D ^j  

^a UNIVERSITY OF VERMONT   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f Orange Pathology Associates   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ MAYO CLINIC   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ATELECTASIS; BRONCHOSCOPY; BRONCHUS; CANCER DIAGNOSIS; CANCER INVASION; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CARCINOID; CLINICAL PROTOCOL; GENE MUTATION; HISTOLOGY; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; LUNG HILUS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; LYMPH NODE; LYMPH NODE METASTASIS; MUTATIONAL ANALYSIS; PATHOLOGY; PLEURA EFFUSION; PLEURA TUMOR; PNEUMONIA; REVIEW; TREATMENT RESPONSE; VISCERAL METASTASIS; WORLD HEALTH ORGANIZATION;

CARCINOID TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CLINICAL PROTOCOLS; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATHOLOGY, SURGICAL; SOCIETIES, MEDICAL; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 70349804501     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Rami-Porta R, Ball D, Crowley J, et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2(7):593-602. (Pubitemid 47171780)
2. Postmus P, Brambilla E, Chansky K, et al. The IASLC lung cancer staging project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol. 2007;2(8):686-693. (Pubitemid 47357520)
3. Martini M, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70(4):606-612.
4. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004. World Health Organization Classification of Tumours; vol 7.
5. Travis WD, Giroux DJ, Chansky K, et al. The IASLC lung cancer staging project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2008;3(11):1213-1223.
6. Mountain CF. The international system for staging lung cancer. Semin Surg Oncol. 2000;18(2):106-125.
7. Bunker ML, Raab SS, Landreneau RJ, Silverman JF. The diagnosis and significance of visceral pleura invasion in lung carcinoma: histologic predictors and the role of elastic stains. Am J Clin Pathol. 1999;112(6):777-783.
8. Shimizu K, Yoshida J, Nagai K, et al. Visceral pleural invasion classification in non-small cell lung cancer: a proposal on the basis of outcome assessment. J Thorac Cardiovasc Surg. 2004;127(6):1574-1578. (Pubitemid 38725433)
9. Hammar SP. Common neoplasms. In: Dail DH, Hammar SP, eds. Pulmonary Pathology. 2nd ed. New York, NY: Springer-Verlag; 1994:1123-1278.
10. Travis WD, Brambilla E, Rami-Porta R, et al. Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2008;3(12):1384-1390.
11. Lung. In: Edge SB, Byrd DR, Carducci MA, Compton CC, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009.
12. Collaborative Staging Task Force of the American Joint Committee on Cancer. Collaborative Staging Manual and Coding Instructions. Version 01.03.00. Chicago, IL: American Joint Committee on Cancer, and Bethesda, MD: US Department of Health and Human Services. 2004. National Institutes of Health publication 04-5496; with updates through September 8, 2006.
13. Junker K, Langer K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest. 2001;120(5):1584-1591. (Pubitemid 33078476)
14. Marchevsky AM. Problems in pathologic staging of lung cancer. Arch Pathol Lab Med. 2006;130(3):292-302.
15. Brechot JM, Chevret S, Charpentier MC, et al. Blood vessel and lymphatic vessel invasion in resected non-small cell lung carcinoma. Cancer. 1996;78(10):2111-2118.
16. Sobin LH, Gospodarowicz M, Wittekind CH, eds. UICC TNM Classification of Malignant Tumours. 7th ed. New York, NY: Wiley-Liss; 2009.
17. Stahel R, Ginsberg R, Havemann K, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer. 1989;5(4-6):119-126. (Pubitemid 20053516)
18. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 2007;2(12):1067-1077. (Pubitemid 350307898)
19. Flieder DB. Commonly encountered difficulties in pathologic staging of lung cancer. Arch Pathol Lab Med. 2007;131(7):1016-1026.
20. Riquet M, Manac'h D, Saab M, Le Pimpec-Barthes F, Dujon A, Debesse B. Factors determining survival in N2 lung cancer. Eur J Cardiothorac Surg. 1995;9(6):300-304.
21. Mountain CF. The evolution of the surgical treatment of lung cancer. Chest Surg Clin North Am. 2000;10(1):83-104. (Pubitemid 30080652)
22. Coughlin M, Deslauriers J, Beaulieu M, et al. Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. Ann Thorac Surg. 1985;40(6):556-560. (Pubitemid 16186099)
23. Rusch VW, Crowley J, Giroux DJ, et al. The IASLC lung cancer staging project: proposals for the revision for the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2(7):603-612. (Pubitemid 47171781)
24. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111(6):1718-1723. (Pubitemid 27260108)
25. Japan Lung Cancer Society. Classification of Lung Cancer. 1st English ed. Tokyo, Japan: Kanehara & Co; 2000.
26. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500. (Pubitemid 38720929)
27. Daniele L, Macri L, Schena M, et al. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther. 2007;6(4):1223-1229. (Pubitemid 46711985)
28. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97(9):643-655. (Pubitemid 40812628)
29. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21(20):3798-3807. (Pubitemid 46606235)
30. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32(6):810-827.
31. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PloS Med. 2005;2(3):e73. http://www.plosmedicine.org/ article/info%3Adoi%2F10.1371%2Fjournal.pmed.0020073. Accessed May 18, 2009. (Pubitemid 40629469)
32. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001;92(6):1525-1530. (Pubitemid 32947838)
33. Tsao M, Zhy C, Sakurada A, et al. An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer. J Clin Oncol. 2006;24(18s)(suppl). Abstract 7005.